Report of a parent survey of high CBD cannabis use in pediatric treatment-resistant epilepsy

(find the full article here)

Severe childhood epilepsies are characterized by frequent seizures, neurodevelopmental delays, and impaired quality of life. In these treatment-resistant epilepsies, families often seek alternative treatments. This survey explored the use of cannabidiol-enriched cannabis in children with treatment-resistant epilepsy. The survey was presented to parents belonging to a Facebook group dedicated to sharing information about the use of cannabidiol-enriched cannabis to treat their child's seizures. Nineteen responses met the following inclusion criteria for the study: a diagnosis of epilepsy and current use of cannabidiol-enriched cannabis. Thirteen children had Dravet syndrome, four had Doose syndrome, and one each had Lennox–Gastaut syndrome and idiopathic epilepsy. The average number of antiepileptic drugs (AEDs) tried before using cannabidiol-enriched cannabis was 12. Sixteen (84%) of the 19 parents reported a reduction in their child's seizure frequency while taking cannabidiol-enriched cannabis. Of these, two (11%) reported complete seizure freedom, eight (42%) reported a greater than 80% reduction in seizure frequency, and six (32%) reported a 25–60% seizure reduction. Other beneficial effects included increased alertness, better mood, and improved sleep. Side effects included drowsiness and fatigue. Our survey shows that parents are using cannabidiol-enriched cannabis as a treatment for their children with treatment-resistant epilepsy. Because of the increasing number of states that allow access to medical cannabis, its use will likely be a growing concern for the epilepsy community. Safety and tolerability data for cannabidiol-enriched cannabis use among children are not available. Objective measurements of a standardized preparation of pure cannabidiol are needed to determine whether it is safe, well tolerated, and efficacious at controlling seizures in this pediatric population with difficult-to-treat seizures.


We need more info about Cannabis & Epilepsy. Submit your favorite link or video.


Can we help with your Child's Epilepsy?


No guarantees!

However, according to the results scientists and other people are finding, the chances seem to be promising enough that it could be worth giving CBD a try.

We produce tinctures from our CBD plant strains that contain so little THC that there is ZERO "high" effect.

The THC content is below 1% while the CBD content ranges up to 50% in concentrate form.

Our tinctures are diluted with the specific goal of creating a strong enough dose of CBD to be effective, while still keeping the cost reasonable.

We strongly reccomend that you consult a physician before giving any herbal Dietary Supplements to yourself, or a child. And as with all Cannabis dosing, always start out small and progress slowly up in dosage if no adverse affects are observed.




Test results from our "House" strain Concentrate

Note: the law does state the limit at 0.3% from dry plant matter.
This test is from the most concentrated oil we can possibly get out of this plant and it still only went 0.2% over the limit.

The dry plant matter always has a FAR lower concentration of everything.



Ladybud Article about results one family is getting with THC & CBD oils.









Cannabis is NOT an FDA approved medicine. All our products are considered "Dietary Supplements" and are not claimed to diagnose, treat, cure or prevent any disease. Information About Herbs, Botanicals and Other Products — is for general health information only. This Web site is not to be used as a substitute for medical advice. Users of this Web site should not rely on the information provided here as the sole source of information for their own health problems. Any questions regarding your health should be addressed to your physician or other licensed healthcare provider.

All information and the recipes for the products on this website are Copyright Glen Johnson - Natures Meds 2015

Natures Meds is located in Eugene, Oregon.